DE60233434D1 - Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie - Google Patents

Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Info

Publication number
DE60233434D1
DE60233434D1 DE60233434T DE60233434T DE60233434D1 DE 60233434 D1 DE60233434 D1 DE 60233434D1 DE 60233434 T DE60233434 T DE 60233434T DE 60233434 T DE60233434 T DE 60233434T DE 60233434 D1 DE60233434 D1 DE 60233434D1
Authority
DE
Germany
Prior art keywords
amino acids
units
amino
oligopeptides
methacryloylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233434T
Other languages
German (de)
English (en)
Inventor
Karel Ulbrich
Tomas Etrych
Blanka Rihova
Marketa Jelinkova
Marek Kovar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Application granted granted Critical
Publication of DE60233434D1 publication Critical patent/DE60233434D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60233434T 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie Expired - Lifetime DE60233434D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
PCT/CZ2002/000070 WO2003053473A2 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug

Publications (1)

Publication Number Publication Date
DE60233434D1 true DE60233434D1 (de) 2009-10-01

Family

ID=5473644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233434T Expired - Lifetime DE60233434D1 (de) 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Country Status (18)

Country Link
US (1) US7919076B2 (https=)
EP (2) EP1782833A3 (https=)
JP (1) JP4718117B2 (https=)
KR (1) KR20040076874A (https=)
AT (1) ATE439864T1 (https=)
AU (1) AU2002366715A1 (https=)
CA (1) CA2470976A1 (https=)
CZ (1) CZ293787B6 (https=)
DE (1) DE60233434D1 (https=)
DK (1) DK1463529T5 (https=)
EA (1) EA007353B1 (https=)
ES (1) ES2331303T3 (https=)
HU (1) HUP0500541A3 (https=)
PL (1) PL216518B1 (https=)
PT (1) PT1463529E (https=)
SI (1) SI1463529T1 (https=)
SK (1) SK2912004A3 (https=)
WO (1) WO2003053473A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294996B6 (cs) * 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
CZ297827B6 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
CZ299053B6 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
EP2056106B1 (en) 2006-08-09 2017-10-11 Sumitomo Bakelite Company, Ltd. Sugar chain-capturing substance and use thereof
CZ2006592A3 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
ES2532656T3 (es) 2007-04-30 2015-03-30 Arqule, Inc. Compuestos de hidroxi sulfonato de quinona y sus usos
CZ301288B6 (cs) * 2008-10-23 2009-12-30 Zentiva, A. S Polymerní prípravek se synergickým úcinkem pri lécbe nádorových onemocnení
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
WO2018071767A1 (en) 2016-10-14 2018-04-19 University Of Utah Research Foundation Antibody-polymer-drug conjugates
WO2020214858A1 (en) * 2019-04-17 2020-10-22 Avidea Technologies, Inc. Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
CZ309828B6 (cs) * 2019-10-09 2023-11-15 I.T.A.-Intertact S.R.O. Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití
US12558432B2 (en) 2019-10-30 2026-02-24 Cis Biopharma Ag Biocompatible polymeric drug carriers for delivering active agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs

Also Published As

Publication number Publication date
ATE439864T1 (de) 2009-09-15
WO2003053473A3 (en) 2004-04-29
EP1463529A2 (en) 2004-10-06
EA200400802A1 (ru) 2005-02-24
SK2912004A3 (en) 2004-12-01
JP4718117B2 (ja) 2011-07-06
US7919076B2 (en) 2011-04-05
CZ20014653A3 (cs) 2003-08-13
CZ293787B6 (cs) 2004-07-14
WO2003053473A2 (en) 2003-07-03
EP1463529B9 (en) 2011-03-23
HUP0500541A2 (hu) 2005-09-28
PL370719A1 (en) 2005-05-30
HUP0500541A3 (en) 2011-08-29
ES2331303T9 (es) 2011-08-18
AU2002366715A1 (en) 2003-07-09
PT1463529E (pt) 2009-11-03
ES2331303T3 (es) 2009-12-29
PL216518B1 (pl) 2014-04-30
DK1463529T3 (da) 2009-10-19
JP2005519044A (ja) 2005-06-30
KR20040076874A (ko) 2004-09-03
US20060057099A1 (en) 2006-03-16
EP1782833A3 (en) 2008-03-19
EP1782833A2 (en) 2007-05-09
DK1463529T5 (da) 2011-06-27
SI1463529T1 (sl) 2010-01-29
EA007353B1 (ru) 2006-10-27
AU2002366715A8 (en) 2003-07-09
CA2470976A1 (en) 2003-07-03
EP1463529B1 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
DE60233434D1 (de) Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie
CN120248019B (zh) 生物活性物偶联物及其制备方法和用途
US7893023B2 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
CY1117065T1 (el) Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων
BR0013577A (pt) Efetores de dipeptidil peptidase iv para uso tópico
TR200200252T2 (tr) Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
CY1108465T1 (el) Μεθοδος συνθεσης πεπτιδιων στερεης φασης
PA8497801A1 (es) Conjugados de eritropoyetina
ATE437647T1 (de) Transporter mit beabstandeten arginin-teilchen
KR20110022594A (ko) 신규한 이중 표적화 항종양성 접합체
JP2005519044A5 (https=)
DK0437563T3 (da) Bioligiske aktive lægemiddelpolymerderivater
CA2657476C (en) Protein-binding methotrexate derivatives and medicaments containing the same
Lutsenko et al. Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment
CN1056084C (zh) 抗与表面抗原相关的cd33的免疫毒素
Pechar et al. Conjugates of Antibody‐Targeted PEG Multiblock Polymers with Doxorubicin in Cancer Therapy
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
Komazawa et al. Inhibition of tumor metastasis by a synthetic polymer containing a cell-adhesive RGDS peptide
Miklán et al. Cell-penetrating and targeting peptide conjugates of antitumor drugs: Synthesis, chemical and in vitro biological characterization
Říhová et al. Targetable photoactivatable drugs
Watson Development of Amphipathic Beta-Strand Mimics as Potential Membrane Active Antibiotics
JPH06157347A (ja) 選択性制癌剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition